Contributions
Abstract: PB1791
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
Bendamustine is one of the chemotherapy agents widely used today in patients with lymphoma. Its impact on the yield of peripheral blood stem cells is not well known.
Aims
The aim of this study was to evaluate the influence of bendamustine as the last previous regimen used before hematopoietic stem cell (HSC) mobilization on HSC collected in patients with lymphoma, and to compare them with a group that has not received bendamustine.
Methods
This is a retrospective, multicenter study, which includes patients from 6 different centers in Spain. Nineteen patients who received bendamustine followed immediately by stem cell mobilization (SCM) were included. A single-center control group of consecutive patients was included, matched by histology, age and number of previous lines.
Results
Table 1 shows the characteristics of the included patients and the control group. Both groups are adequately balanced. No patients received previous lenalidomide, and none patient had previous transplant. The median number of bendamustine cycles was 3.6 (range 2-6). In most of the patients, the mobilization scheme was G-CSF 10 mg/Kg every 24 hours, although 7 patients in the bendamustine group received G-CSF 10 mg/Kg erery 12 hours, and 3 patients in each group were mobilized with G-CS plus chemotherapy. Median days of apheresis with the first attempt was 1.7 in the bendamustine group vs 1,4 in the control group, however in bendamustine group 3 patients didn’t go to apheresis due to a low CD34 cell count in peripheral blood. Plerixafor was needed in 3 cases in the bendamustine group on the first attempt of mobilization, and in other 3 in the second attempt, but in any patient in the control group. In the bendamustine group, 7 patients required a second mobilization attempt (p= 0.003), 3 collected with the 2nd attempt and 1 with the 3rd, and 3 patients were unable to mobilize, none in the control group (p= 0.008). The median number of mobilized CD34 cells obtained with the first apheresis was 3.64x106/kg (range 0-9.6 64x106/kg) in the bendamustine group and 5.5x106/kg (range 1.1-10.4 64x106/kg ) in the control (p = 0.003). No relationship was found between lymphoma histology, stage, doses, or number of cycles of bendamustine administered with the need of a second attempt or mobilization failure.
Patient characteristics | Benda. (n=19) | No Benda. (n=19) | p |
Median age, years | 53 (24-70) | 50 (30-72) | 0.29 |
Sex (male) | 57% | 68% | 0.45 |
Diagnosis | FL 7 MCL 4 HL 4 Others 4 | 9 2 3 5 | 0.11 |
Stage at diagnosis | Localized 4 Advanced 15 | 4 15 | 0.6 |
BM involvement at diagnosis | 47% | 57% | 0.19 |
Previous chemo lines, median (range) | 2 (1-3) | 2 (1-3) | 0.91 |
Pre-apheresis leucocytes, x109/L | 5.3 (1.6-12.3) | 8.3 (1.5-20) | 0.31 |
Pre-apheresis hemoglobin, g/dl | 11.8 (9-12.3) | 11.3 (8.9-13.1) | 0.26 |
Benda. bendamustine. FL follicular lymphoma. MCL mantle cell lymphoma. HL Hodgkin lymphoma
Conclusion
Based on our results, we can conclude that bendamustine used immediately prior to mobilization could negatively affect the collection of HSC in lymphoma patients. We are expanding our series to confirm these results.
Keyword(s): Bendamustine, Lymphoma, Mobilization
Abstract: PB1791
Type: Publication Only
Session title: Stem cell transplantation - Clinical
Background
Bendamustine is one of the chemotherapy agents widely used today in patients with lymphoma. Its impact on the yield of peripheral blood stem cells is not well known.
Aims
The aim of this study was to evaluate the influence of bendamustine as the last previous regimen used before hematopoietic stem cell (HSC) mobilization on HSC collected in patients with lymphoma, and to compare them with a group that has not received bendamustine.
Methods
This is a retrospective, multicenter study, which includes patients from 6 different centers in Spain. Nineteen patients who received bendamustine followed immediately by stem cell mobilization (SCM) were included. A single-center control group of consecutive patients was included, matched by histology, age and number of previous lines.
Results
Table 1 shows the characteristics of the included patients and the control group. Both groups are adequately balanced. No patients received previous lenalidomide, and none patient had previous transplant. The median number of bendamustine cycles was 3.6 (range 2-6). In most of the patients, the mobilization scheme was G-CSF 10 mg/Kg every 24 hours, although 7 patients in the bendamustine group received G-CSF 10 mg/Kg erery 12 hours, and 3 patients in each group were mobilized with G-CS plus chemotherapy. Median days of apheresis with the first attempt was 1.7 in the bendamustine group vs 1,4 in the control group, however in bendamustine group 3 patients didn’t go to apheresis due to a low CD34 cell count in peripheral blood. Plerixafor was needed in 3 cases in the bendamustine group on the first attempt of mobilization, and in other 3 in the second attempt, but in any patient in the control group. In the bendamustine group, 7 patients required a second mobilization attempt (p= 0.003), 3 collected with the 2nd attempt and 1 with the 3rd, and 3 patients were unable to mobilize, none in the control group (p= 0.008). The median number of mobilized CD34 cells obtained with the first apheresis was 3.64x106/kg (range 0-9.6 64x106/kg) in the bendamustine group and 5.5x106/kg (range 1.1-10.4 64x106/kg ) in the control (p = 0.003). No relationship was found between lymphoma histology, stage, doses, or number of cycles of bendamustine administered with the need of a second attempt or mobilization failure.
Patient characteristics | Benda. (n=19) | No Benda. (n=19) | p |
Median age, years | 53 (24-70) | 50 (30-72) | 0.29 |
Sex (male) | 57% | 68% | 0.45 |
Diagnosis | FL 7 MCL 4 HL 4 Others 4 | 9 2 3 5 | 0.11 |
Stage at diagnosis | Localized 4 Advanced 15 | 4 15 | 0.6 |
BM involvement at diagnosis | 47% | 57% | 0.19 |
Previous chemo lines, median (range) | 2 (1-3) | 2 (1-3) | 0.91 |
Pre-apheresis leucocytes, x109/L | 5.3 (1.6-12.3) | 8.3 (1.5-20) | 0.31 |
Pre-apheresis hemoglobin, g/dl | 11.8 (9-12.3) | 11.3 (8.9-13.1) | 0.26 |
Benda. bendamustine. FL follicular lymphoma. MCL mantle cell lymphoma. HL Hodgkin lymphoma
Conclusion
Based on our results, we can conclude that bendamustine used immediately prior to mobilization could negatively affect the collection of HSC in lymphoma patients. We are expanding our series to confirm these results.
Keyword(s): Bendamustine, Lymphoma, Mobilization